Alpha 2.0
Login Register
» Authors » B D Palmer

B D Palmer

Explore the profile of B D Palmer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 58
Citations 368
Followers 0
Related Specialties
Chemistry
Oncology
Pharmacology
Top 10 Co-Authors
W A Denny
W R Wilson
B C Baguley
G W Rewcastle
L J Guillette Jr
H D Showalter
I G Robertson
D W FRY
M Boyd
A J Kraker
Published In
J Med Chem
Br J Cancer
Gen Comp Endocrinol
Biochem Pharmacol
Anticancer Drug Des
Affiliations
Soon will be listed here.
Recent Articles
1.
Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
Tijono S, Guo K, Henare K, Palmer B, Wang L, Albelda S, et al.
Br J Cancer . 2013 Mar; 108(6):1306-15. PMID: 23481185
Background: Species selectivity of DMXAA (5,6-dimethylxanthenone-4-acetic acid, Vadimezan) for murine cells over human cells could explain in part the recent disappointing phase III trials clinical results when preclinical studies were...
2.
Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver
Dogra M, Palmer B, Bashiri G, Tingle M, Shinde S, Anderson R, et al.
Br J Pharmacol . 2010 Oct; 162(1):226-36. PMID: 20955364
Background And Purpose: PA-824 is a 2-nitroimidazooxazine prodrug currently in Phase II clinical trial for tuberculosis therapy. It is bioactivated by a deazaflavin (F(420) )-dependent nitroreductase (Ddn) isolated from Mycobacterium...
3.
Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5
Kestell P, Pruijn F, Siim B, Palmer B, Wilson W
Cancer Chemother Pharmacol . 2000 Dec; 46(5):365-74. PMID: 11127940
Purpose: To characterise the pharmacokinetics and metabolism in mice of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862), the lead compound of a new class of bioreductive drugs in which a nitrogen mustard is activated...
4.
Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide
Kestell P, Zhao L, Baguley B, Palmer B, Muller G, Paxton J, et al.
Cancer Chemother Pharmacol . 2000 Sep; 46(2):135-41. PMID: 10972483
Background: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), an investigative drug currently in clinical trial, acts on tumour vasculature through the induction of cytokines. Coadministration of thalidomide, a modulator of cytokine production, potentiates the...
5.
Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs
Screnci D, McKeage M, Galettis P, Hambley T, Palmer B, Baguley B
Br J Cancer . 2000 Mar; 82(4):966-72. PMID: 10732773
Previous work has shown platinum drugs to differ in their effects on the peripheral nervous system. To test whether their differential toxicity was due to differences in their partitioning into...
6.
Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor
Palmer B, Kraker A, Hartl B, Panopoulos A, Panek R, Batley B, et al.
J Med Chem . 1999 Jul; 42(13):2373-82. PMID: 10395478
Following an earlier discovery of 1-phenylbenzimidazoles as ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR), further structure-activity relationships for analogues (particularly 5-substituted derivatives) are reported. The data are consistent...
7.
Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
Cao Z, Joseph W, Browne W, Mountjoy K, Palmer B, Baguley B, et al.
Br J Cancer . 1999 Jun; 80(5-6):716-23. PMID: 10360649
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), synthesized in this laboratory and currently in phase I clinical trial, is a low molecular weight inducer of tumour necrosis factor-alpha (TNF-alpha). Administration of DMXAA to mice...
8.
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor
Smaill J, Palmer B, Rewcastle G, Denny W, McNamara D, Dobrusin E, et al.
J Med Chem . 1999 May; 42(10):1803-15. PMID: 10346932
A series of 6- and 7-acrylamide derivatives of the 4-(phenylamino)quinazoline and -pyridopyrimidine classes of epidermal growth factor receptor (EGFR) inhibitors were prepared from the corresponding amino compounds by reaction with...
9.
Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor
Palmer B, Smaill J, Boyd M, Boschelli D, Doherty A, Hamby J, et al.
J Med Chem . 1999 Jan; 41(27):5457-65. PMID: 9876115
1-Phenylbenzimidazoles are shown to be a new class of ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR). Structure-activity relationships (SARs) are narrow, with closely related heterocycles being inactive. A...
10.
Synthesis and hypoxia-selective cytotoxicity of a 2-nitroimidazole mustard
Lee H, Palmer B, Wilson W, Denny W
Bioorg Med Chem Lett . 1999 Jan; 8(13):1741-4. PMID: 9873426
A four-step synthesis of 5-[N,N-bis(2-chloroethyl)amino]-1-methyl-2-nitroimidazole from 1-methyl-2-nitroimidazole is described. This compound showed similar hypoxia-selective cytotoxicity to the dinitrobenzamide mustard SN 23,862 in UV4 cells (ca. 40-fold), and superior selectivity (>...